Astellas | pharmaphorum

Thursday 28 November 2024

Channels

Content type

Categories

Categories

Sort by

Order

Astellas

News

Xtandi

Trial could unlock new prostate cancer sales for Pfizer/Aste...

Pfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but has not yet become hormone resistant, stepping up pressure on rival therapy Zytiga from Johnson

News

Bayer/Orion showcase results from prostate cancer challenger

Bayer/Orion showcase results from prostate cancer challenger

Bayer and development partner Orion have released detailed results from the trial that will form the backbone of its filing for their latest prostate cancer drug, as they aim to take on two

News

Astellas gains three cancer drugs with $405m Potenza buy

Astellas gains three cancer drugs with $405m Potenza buy

Astellas has taken an option to acquire US biotech Potenza Therapeutics after the companies spent more than three years working together on cancer immunotherapies.

News

Astellas scores first US blood cancer approval with Xospata

Astellas scores first US blood cancer approval with Xospata

The FDA has approved Astellas’ Xospata for certain patients with acute myeloid leukaemia – the company’s first drug approved in blood cancer.

Partner Content

Jo-Taylor-PharmaPhorum

Partner Content

Corporate Communications chief of Astellas, Jo Taylor moves ...

Jo Taylor moves to Cello Health Communications

News

Mature Woman Experiencing Hot Flush From Menopause

UK's KaNDy Therapeutics funds mid-stage trial of HRT 'replac...

Biotech hopes for IPO or big pharma deal to fund phase 3